5 mg: 3001000 mcg per injection with gradual titration
In comparative receptor pharmacology, semaglutide is a GLP-1 receptor monoagonist, tirzepatide is a dual GLP-1/GIP agonist, and GLP-3 (RT) adds a third receptor target: the glucagon receptor
These typically peak during weeks 4 to 8 of treatment, coinciding with dose escalation, then resolve by week 12 for most people
These trials are now standard in the GLP-1 drug class -- semaglutide's SELECT trial demonstrated a 20% reduction in MACE, leading to a cardiovascular indication for Wegovy
Handling & Reconstitution (Research Use) Retatrutide lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS)
New or worsening depression should be addressed, as fatigue is a common symptom of mood disorders